Search
Now showing items 41-50 of 142
The effects of oncolytic Maraba virus (MG1) in advanced non-small cell lung cancer
(Institute of Cancer Research (University Of London), 2021-08-31)
Lung cancer is responsible for the highest cancer mortality worldwide. The prognosis for patients with advanced disease remains poor with five-year overall survival of <10%, highlighting the urgent unmet need for novel ...
Investigating the molecular mechanisms of fraction size sensitivity in irradiated cells
(Institute of Cancer Research (University Of London), 2020-09-30)
Fractionated radiotherapy is used clinically when it spares healthy tissue relative to the cancer; the healthy tissue is described as more fraction size sensitive. However, a molecular understanding of the mechanisms that ...
An exploration of mechanisms and effects of oncogenic KRAS on the tumour immune microenvironment
(Institute of Cancer Research (University Of London), 2022-07-06)
Oncogenic KRAS influences several cancer hallmarks including autonomy from growth promoting signals, enhanced cell survival and altered tumour metabolism. Beyond these, it is now established that oncogenic KRAS can polarise ...
Optimising head and neck radiotherapy treatment using adaptive radiotherapy
(Institute of Cancer Research (University Of London), 2021-10-31)
Radiotherapy delivery in head and neck cancer (HNC) has dramatically improved recently with the introduction of advanced techniques such as intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy ...
Developing biomarker-driven treatments for oesophagogastric cancer
(Institute of Cancer Research (University Of London), 2020-08-31)
Introduction Despite recent advances in both genetic characterisation and development of novel targeted agents the outlook for advanced oesophagogastric (OG) cancers remain poor and there is a need for improved biomarker-driven ...
Amino acid dependence in acute myeloid leukaemia
(Institute of Cancer Research (University Of London), 2022-05-31)
Acute myeloid leukaemia (AML) is a heterogeneous disease which remains curable in only a minority of patients. Outcome is dismal in the subgroup with adverse genetic features. Amino acid (AA) depletion is a therapeutic ...
Using inducible degradation to characterise the roles of TRIP13 and CEP57 in mitosis
(Institute of Cancer Research (University Of London), 2021-05-31)
DNA and centrosomes are both semi-conservatively replicated once per cell cycle and it is essential that the DNA and centrosomes are divided equally between daughter cells in mitosis. When this fails, it can lead to ...
Deciphering genetic susceptibility to multiple myeloma
(Institute of Cancer Research (University Of London), 2020-09-30)
Multiple myeloma (MM) is a malignancy characterised by the clonal expansion of plasma cells primarily from the bone marrow. The two- to four-fold increased risk observed in relatives of MM patients provides support for ...
Three-dimensional dose verification of adaptive radiotherapy at an MR-linac
(Institute of Cancer Research (University Of London), 2020-04-30)
The vision of accurate real-time image-guided radiotherapy (RT) has led to the development of MR-Linacs consisting of MRI scanners integrated within RT treatment units. The safe clinical operation of these devices requires ...
Investigating a range of late effects of Hodgkin lymphoma treatments
(Institute of Cancer Research (University Of London), 2021-01-31)
Dramatic improvement in Hodgkin lymphoma (HL) survival rates over recent decades has come at significant cost: treatment-related late effects which are epitomised in female HL patients treated at young ages. The aims of ...